ArticleAsian Pacific journal of cancer prevention : APJCP2018
Proliferative Index (Ki67) for Prediction in Breast Duct Carcinomas
Article in Asian Pacific journal of cancer prevention : APJCP, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 18 citations in OpenAlex.
- Proliferative Markers in Breast Cancer and Chemotherapy Implications: A Comprehensive Review.Health science reports · 2025Article
- The 1000 Mitoses Project: A Consensus-Based International Collaborative Study on Mitotic Figures Classification.International journal of surgical pathology · 2024Article
- The Role of miRNAs in the Prognosis of Triple-Negative Breast Cancer: A Systematic Review and Meta-Analysis.Diagnostics (Basel, Switzerland) · 2022Review
- Arterial Spin Labeling Perfusion in Determining the IDH1 Status and Ki-67 Index in Brain Gliomas.Diagnostics (Basel, Switzerland) · 2022Article
- Epigenetic alterations at distal enhancers are linked to proliferation in human breast cancer.NAR cancer · 2022Article
- Fatty acid synthetase expression in triple-negative breast cancer.Journal of pathology and translational medicine · 2022Article
- Immunohistochemical Expression of BRCA1 Protein, ER, PR and Her2/neu in Breast Cancer: A Clinicopathological Study.Asian Pacific journal of cancer prevention : APJCP · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and objectives: To date, many tumor markers have been used to predict prognosis and therapeutic response in patients with breast cancer. The well established and routinely applied tumor markers are the estrogen-receptor, progesterone-receptor and Her2/neu-receptor. In the current study, we aimed to highlight any association of the proliferation index (Ki67) in breast infiltrative duct carcinoma with the tumor grade, tumor size and nodal status in addition to hormone receptor status. Tissue sections were stained immunohistochemically for Ki67 nuclear antigen, estrogen, progesterone and Her2/neu receptors using an automated Dako machine (Dako Denmark. There was a significant inverse relationship of Ki67 levels with ER and PR, while values were directly proportional to the tumor grade and Her2/neu status. No significant association was found between Ki67 and size of tumor or nodal status. Ki67 immunoexpression may offer an independent predictive tumor marker and for routine application in cases of breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.